Alzheimer's disease drug development pipeline: 2022

Insights and discussion from the cutting edge with reference to journal articles and other research papers.
Post Reply
BrianR
Senior Contributor
Senior Contributor
Posts: 276
Joined: Tue Oct 02, 2018 12:32 pm
Location: Central Florida

Alzheimer's disease drug development pipeline: 2022

Post by BrianR »

Open access.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066743/

Alzheimer's disease drug development pipeline: 2022
Jeffrey Cummings,corresponding author, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Fonseca, and Kazem Taghva
Alzheimers Dement (N Y). 2022; 8(1): e12295.
Published online 2022 May 4. doi: 10.1002/trc2.12295

2022AlzheimerPipeline.png
Figure 1. Agents in clinical trials for treatment of Alzheimer's disease in 2021 (from clinicaltrials.gov as of the index date of January 5, 2021). The inner ring shows Phase 3 agents; the middle ring comprises Phase 2 agents; the outer ring presents Phase 1 therapies; agents in green areas are biologics; agents in purple are disease‐modifying small molecules; agents in orange areas are symptomatic agents addressing cognitive enhancement or behavioral and neuropsychiatric symptoms; the shape of the icon shows the population of the trial; the icon color shows the Common Alzheimer's Disease Research Ontology (CADRO)‐based class of the agent (“Other” category includes CADRO classes that have three or fewer agents in trials). Agents underlined are new to the pipeline since 2020. (Figure © J Cummings; M de la Flor, PhD, Illustrator)
You do not have the required permissions to view the files attached to this post.
User avatar
SusanJ
Senior Contributor
Senior Contributor
Posts: 2987
Joined: Wed Oct 30, 2013 7:33 am
Location: Western Colorado

Re: Alzheimer's disease drug development pipeline: 2022

Post by SusanJ »

Thanks for sharing. Interesting to read all the various targets of these drug trials.
The targets include amyloid; tau; apolipoprotein E (APOE)/lipids, and lipoprotein receptors; neurotransmitter receptors; neurogenesis; inflammation; oxidative stress; cell death; proteostasis/proteinopathies; metabolism and bioenergetics; vasculature; growth factors and hormones; synaptic plasticity/neuroprotection; gut‐brain axis; circadian rhythm; epigenetic regulators; multi‐target; unknown target, and other.
JulieAnnie
Senior Contributor
Senior Contributor
Posts: 72
Joined: Mon Jul 28, 2014 10:38 am

Re: Alzheimer's disease drug development pipeline: 2022

Post by JulieAnnie »

Great to see Montelukast in Phase 2 studies for prodromal and mild to mod dementia. Effective so far in inflammation and immunity issues.
JulieAnnie
Senior Contributor
Senior Contributor
Posts: 72
Joined: Mon Jul 28, 2014 10:38 am

Re: Alzheimer's disease drug development pipeline: 2022

Post by JulieAnnie »

Great to see Montelukast in Phase 2 studies for prodromal and mild to mod dementia. Effective so far in inflammation and immunity issues.
Post Reply